RevBio earned a $2.2 million grant from the National Institute on Aging, part of the National Institutes of Health to research Tetranite in minimally invasive spine fracture care, according to an Oct. 6 news release.
The grant will support preclinical research in Tetranite, a biomaterial injectable bone adhesive. RevBio’s grant is for two years and builds on work done in with a Phase I grant.
“The adhesive and structural features of this biomaterial combined with the fact that it is osteoconductive and ultimately replaced by bone make it an excellent candidate for an improved vertebroplasty procedure,” neurosurgeon Kevin Foley, MD, PhD, said in the release.
